Evidence map›Paper›PMID 28928429›Full record

ArticleScientific reports2017

Nrf2/HO-1 mediates the neuroprotective effect of mangiferin on early brain injury after subarachnoid hemorrhage by attenuating mitochondria-related apoptosis and neuroinflammation.

Zefeng Wang, Songxue Guo, Junxing Wang, Yuanyuan Shen, Jianmin Zhang, Qun Wu

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Acute Supplementation of Soluble Mango Leaf Extract (ZynamitePharmaceuticals (Basel, Switzerland) · 2025
    Article
  4. Mitochondrial-targeted therapies in traumatic brain injury: From bench to bedside.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Pharmacological Effects ofPharmaceuticals (Basel, Switzerland) · 2022
    Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Zefeng WangDepartment of Neurosurgery, Second Affiliated Hospital, Zhejiang University, College of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China.
Songxue GuoDepartment of Plastic surgery, Second Affiliated Hospital, Zhejiang University, College of Medicine, 1511 Jianghong Road, Hangzhou, 310009, Zhejiang, China.ORCID 0000-0001-9019-4723
Junxing WangDepartment of Neurosurgery, Second Affiliated Hospital, Zhejiang University, College of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China.
Yuanyuan ShenDepartment of Neuroscience care unit, Second Affiliated Hospital, Zhejiang University, College of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China.
Jianmin ZhangDepartment of Neurosurgery, Second Affiliated Hospital, Zhejiang University, College of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China.
Qun WuDepartment of Neurosurgery, Second Affiliated Hospital, Zhejiang University, College of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China. wuqun30639@163.com.ORCID 0000-0001-6456-3855
Second Affiliated Hospital of Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early brain injury (EBI) is involved in the process of cerebral tissue damage caused by subarachnoid hemorrhage (SAH), and multiple mechanisms, such as apoptosis and inflammation, participate in its development. Mangiferin (MF), a natural C-glucoside xanthone, has been reported to exert beneficial effects against several types of organ injury by influencing various biological progresses. The current study aimed to investigate the potential of MF to protect against EBI following SAH via histological and biological assessments. A rat perforation model of SAH was established, and MF was subsequently administered via intraperitoneal injection at a low and a high dose. High-dose MF significantly lowered the mortality of SAH animals and ameliorated their neurological deficits and brain edema. MF also dose-relatedly attenuated SAH-induced oxidative stress and decreased cortical cell apoptosis by influencing mitochondria-apoptotic proteins. In addition, MF downregulated the activation of the NLRP3 inflammasome and NF-κB as well as the production of inflammatory cytokines, and the expression of Nrf2 and HO-1 was upregulated by MF. The abovementioned findings indicate that MF is neuroprotective against EBI after SAH and Nrf2/HO-1 cascade may play a key role in mediating its effect through regulation of the mitochondrial apoptosis pathway and activation of the NLRP3 inflammasome and NF-κB.

Indexed as

Brain InjuriesSubarachnoid HemorrhageAnimalsApoptosisHeme Oxygenase (Decyclizing)InflammationMaleMitochondriaNeuroprotective AgentsNF-E2-Related Factor 2RatsRats, Sprague-DawleyXanthonesHeme Oxygenase (Decyclizing)Hmox1 protein, ratmangiferinNeuroprotective AgentsNfe2l2 protein, ratNF-E2-Related Factor 2Xanthones

Identifiers

PMID28928429
PMCPMC5605716
OpenAlexW2754836087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.